<DOC>
	<DOCNO>NCT00047281</DOCNO>
	<brief_summary>RATIONALE : Thalidomide celecoxib may stop growth tumor cell stop blood flow tumor . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining thalidomide celecoxib etoposide cyclophosphamide may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine thalidomide celecoxib etoposide cyclophosphamide treat patient relapse refractory malignant glioma .</brief_summary>
	<brief_title>Thalidomide , Celecoxib , Combination Chemotherapy Treating Patients With Relapsed Refractory Malignant Glioma</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy thalidomide , celecoxib , etoposide , cyclophosphamide , term 6-month progression-free survival , patient relapse refractory malignant glioma . - Determine overall survival patient treat regimen . - Determine toxic effect regimen patient . - Determine radiographic response patient treat regimen . OUTLINE : This multicenter study . Patients receive oral thalidomide daily oral celecoxib twice daily day 1-42 , oral etoposide daily day 1-21 , oral cyclophosphamide daily day 22-42 . Courses repeat every 42 day absence disease progression unacceptable toxicity . Patients follow every 2 month . PROJECTED ACCRUAL : A total 48 patient ( 32 glioblastoma multiforme 16 anaplastic glioma ) accrue study within 2 year .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm intracranial malignant glioma , include glioblastoma multiforme , gliosarcoma , anaplastic astrocytoma , anaplastic oligodendroglioma , anaplastic mixed oligoastrocytoma , malignant astrocytoma otherwise specified Unequivocal evidence relapse refractory disease MRI CT scan and/or tumor resection Steroid therapy prior MRI CT scan must stable dose least 5 day Failed prior radiotherapy Must confirmation true progression rather radiation necrosis previously treat interstitial brachytherapy stereotactic radiosurgery PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 60100 % Life expectancy More 2 month Hematopoietic Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin great 9 g/dL No history bleed disorder Hepatic Bilirubin le 1.5 mg/dL SGPT le 2.5 time normal Alkaline phosphatase less 2.5 time normal Renal Creatinine less 1.5 time upper limit normal ( ULN ) OR BUN le 1.5 time ULN Cardiovascular No deep vein thrombosis within past 3 week ( must clinically stable ) Pulmonary No pulmonary embolism within past 3 week ( must clinically stable ) Other No peripheral neuropathy grade 2 great No active infection No serious concurrent medical illness No concurrent illness may obscure toxicity dangerously alter drug metabolism No malignancy within past 3 year except nonmelanoma skin cancer carcinoma situ cervix Must participate System Thalidomide Education Prescribing Safety program Not pregnant nursing Negative pregnancy test Fertile patient must use 2 form effective contraception 1 month , , 1 month study PRIOR CONCURRENT THERAPY : Biologic therapy No prior oral thalidomide celecoxib 2 month duration Chemotherapy No prior oral etoposide cyclophosphamide 2 month duration Prior standarddose IV etoposide cyclophosphamide allow Endocrine therapy See Disease Characteristics Concurrent steroid allow Radiotherapy See Disease Characteristics At least 4 week since prior radiotherapy Surgery See Disease Characteristics Prior surgery relapse refractory disease allow Recovered prior surgery No concurrent surgery Other No concurrent investigational agent treatment No concurrent anticancer therapy Concurrent antiseizure medication allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2004</verification_date>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>